In vitro thrombosis simulation testing is a core hemocompatibility assay used to evaluate the thrombus-forming tendency of blood-contacting medical devices and biomaterials under controlled laboratory conditions. Performed in accordance with ISO 10993-4 and GB/T 16886.4, the test provides essential data for regulatory submissions, material screening, and surface-modification verification. This article explains the test principles, applicable sample types, evaluation parameters, laboratory methods, and practical applications of in vitro thrombus formation testing.
Technical Overview
In vitro thrombosis simulation testing, also known as in vitro thrombus formation testing or in vitro thrombogenicity assessment, reproduces under laboratory conditions the interaction between blood and the surfaces of blood-contacting medical devices. When blood encounters a foreign material, plasma proteins such as fibrinogen and von Willebrand factor rapidly adsorb onto the surface, platelets adhere and become activated, the coagulation cascade is triggered, and a thrombus forms. The extent and kinetics of thrombus formation provide a direct, quantitative measure of the thrombogenic potential of a device or material.
The test is performed in accordance with ISO 10993-4 (Biological evaluation of medical devices, Part 4: Selection of tests for interactions with blood) and its Chinese counterpart GB/T 16886.4, which identify thrombosis as one of the five hemocompatibility evaluation categories, alongside hematology, coagulation, platelet activation, and complement activation. Supporting practices such as ASTM F1830 guide the selection and handling of blood for in vitro hemocompatibility evaluation. Compared with in vivo animal models, the in vitro approach offers shorter turnaround times, lower cost, improved reproducibility, and reduced animal use, making it a preferred first-line screen in device development and biological safety evaluation.
Testing Samples
External Communicating Devices in Direct Blood Contact
- Intravascular catheters, including central venous, peripheral, arterial, PICC, and hemodialysis catheters
- Infusion sets, extension tubing, stopcocks, syringes, and blood administration sets
- Extracorporeal circulation tubing, blood oxygenators, and cardiotomy reservoirs
- Hemodialysis blood lines, dialyzers, and apheresis kits
- Blood collection systems and blood storage bags
Cardiovascular Implant Devices
- Vascular stents (bare-metal, drug-eluting, and bioresorbable) and stent delivery systems
- Vascular grafts, stent-grafts, and vascular patches
- Heart valve prostheses and annuloplasty rings
- Ventricular assist devices, artificial hearts, and their cannulae
Materials and Surface Modifications
- Polymer films, metal coupons, and tubing segments used in development-stage screening
- Antithrombotic or hydrophilic coatings, such as heparin-bonded or phosphorylcholine-based surfaces
- Surface-textured or chemically modified materials under comparative evaluation
Sample Preparation Requirements
Samples should represent the final product in its clinically relevant, sterilized condition. Test portions are prepared according to the principles of ISO 10993-12, with a defined surface-area-to-blood-volume ratio documented in the test protocol. A negative control, such as medical-grade silicone tubing or an established low-thrombogenic reference material, and a positive control, such as latex or glass surfaces that strongly promote clotting, are tested in parallel to confirm run sensitivity and support comparative interpretation of results.
Testing Items
Depending on the device type, intended blood-contact duration, and study objective, the following endpoints are typically evaluated:
- Thrombus mass, reported as wet weight and dry weight
- Thrombus index, thrombus length, and luminal surface coverage
- Clotting time or kinetic clotting time profile
- Platelet count reduction and platelet adhesion rate
- Platelet activation markers, including CD62P (P-selectin), platelet factor 4, and beta-thromboglobulin
- Blood flow rate reduction and time to luminal occlusion in perfusion models
- Coagulation parameters, such as prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, and thrombin-antithrombin complex
- Morphological characterization of adhered platelets and thrombi by scanning electron microscopy
Testing Methods
Dynamic Thrombosis Test, Chandler Loop Method
The Chandler loop model is the most widely applied in vitro thrombosis simulation technique. Fresh, non-anticoagulated blood from human, rabbit, or bovine donors is drawn and immediately introduced into a closed rotating loop in which the test sample forms part of the tubing wall. The loop rotates at a defined speed inside a 37 °C incubator, subjecting the blood to continuous gravity-driven flow and physiologically relevant shear stress. After a prescribed contact period, commonly 3 to 15 minutes for native blood, the blood is drained from the loop and the thrombus is retrieved, rinsed, and quantified gravimetrically or by hemoglobin assay. Longer contact times may be applied when citrated, recalcified blood is used.
Static Contact and Kinetic Clotting Time Method
In the static configuration, a defined volume of whole blood or recalcified platelet-rich plasma is incubated in direct contact with the test surface at 37 °C. Clotting time is recorded directly, or clot formation is monitored kinetically through serial optical density or gravimetric measurements. A prolonged clotting time relative to the positive control indicates lower thrombogenicity. This configuration is well suited to flat materials, films, coatings, and small device components.
Gravimetric and Hemoglobin-Based Quantification
Thrombus burden is quantified by weighing the retrieved clot before and after drying, with the difference between wet and dry mass reflecting fluid content and clot maturity. Alternatively, the thrombus is lysed and released hemoglobin is measured spectrophotometrically using Drabkin's reagent at approximately 540 nm, with results expressed as hemoglobin mass or thrombus index. Both approaches generate continuous quantitative data suitable for statistical comparison between test samples and controls.
Dynamic Flow Loop and Pulsatile Perfusion Model
For devices exposed to high, pulsatile, or prolonged shear in clinical use, such as heart valves, blood pumps, and oxygenators, a pumped flow loop replicating physiological pressure and flow waveforms may be employed. Endpoints include pressure drop across the device, flow-rate decay, occlusion time, and post-perfusion mapping of thrombus distribution on device surfaces.
Control Design and Data Interpretation
Every test run includes negative and positive controls, and results are interpreted comparatively rather than against absolute pass/fail thresholds defined by the standards. Acceptable thromboresistance is typically demonstrated when the thrombus burden of the test device is statistically comparable to the negative control and significantly lower than the positive control. Because donor blood is inherently variable, standardized blood collection and handling within strict time windows, testing across multiple donors where feasible, and randomized test sequences are essential for data integrity.
Applications
- Generation of the hemocompatibility and thrombosis sections of biological evaluation reports for regulatory submissions, including NMPA registration, FDA 510(k) and IDE filings, and EU MDR conformity assessment
- Screening and selection of polymers, metals, and surface coatings during research and development
- Verification of antithrombotic surface treatment efficacy, such as heparin bonding or hydrophilic coating performance
- Comparative evaluation between device designs, generations, or manufacturing processes
- Batch-to-batch consistency control for blood-contacting components
- Input to risk management documentation per ISO 14971 and scientific justification for reduced or refined in vivo animal testing
FAQ
Q: Which standards govern in vitro thrombosis simulation testing?
A: The primary standards are ISO 10993-4 and GB/T 16886.4, which define the selection of tests for interactions with blood. ASTM F1830 provides supporting guidance on blood selection and handling for in vitro hemocompatibility evaluation. Testing is typically conducted in accredited third-party laboratories or GLP-compliant facilities.
Q: What type of blood is used, and can anticoagulants be added?
A: Fresh, non-anticoagulated blood, typically human or rabbit blood, is preferred because it preserves the complete coagulation cascade. Where anticoagulation is unavoidable, sodium citrate followed by recalcification is the accepted approach. Heparin is generally avoided in static and Chandler loop tests because it directly suppresses thrombus formation and confounds the results.
Q: How long does the test take?
A: The blood-contact phase of a native-blood Chandler loop test typically lasts 3 to 15 minutes, while recalcified or static assays may run longer. Including protocol confirmation, sample preparation, multi-donor testing, and reporting, a complete study generally requires two to four weeks.
Q: What are the acceptance criteria?
A: The standards do not prescribe absolute limits. Performance is judged comparatively: the test device should show thrombus formation statistically comparable to the negative control and significantly lower than the positive control, with platelet count reduction and clotting endpoints evaluated in parallel.
Q: How does the in vitro test differ from in vivo thrombogenicity testing?
A: In vitro testing uses isolated blood under controlled flow and temperature, offering speed, reproducibility, and ethical advantages. In vivo testing in animal models captures vascular wall interactions, sustained blood flow, and physiological repair mechanisms. In vitro results are often used to justify, refine, or reduce subsequent in vivo studies.
Q: What information should be provided when submitting samples?
A: Sponsors should supply the sterilized final product or representative material specimens, product dimensions and blood-contacting surface area, material composition, sterilization method, intended duration of blood contact, and any relevant prior test data, so that the laboratory can select the appropriate model, blood type, and contact protocol.
